Skip to main content

Generics

  • Report: Opioid abuse cost burden exceeds $78 billion

  • Report: Sanofi files suit over Merck’s Lantus biosimilar

  • GPhA’s Davis weighs in on drug costs, generic competition
     
    WASHINGTON — As drug costs again become a topic of national conversation, Chip Davis, president of the Generic Pharmaceutical Association, has weighed in on the issue, noting that one point stakeholders from patients to manufacturers and lawmakers can agree on is the importance of competition in bringing down the cost of drugs. 
     

  • Dr. Reddy’s launches generic Zemplar injection
    HYDERABAD, India and PRINCETON, N.J. — Dr. Reddy’s Laboratories on Monday announced the U.S. launch of its generic of Zemplar (paricalcitol) injection. The drug is indicated to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease stage 5. 
     
    The drug had about $22.5 million in U.S. sales for the 12 months ended July 2016, according to IMS Health. The injection will be available from Dr. Reddy’s in 2-, 5- and 10-mcg dosage strengths. 
     

  • Industry responds to Biosimilar User Fee Act letter
    SILVER SPRING, Md. — The Food and Drug Administration on Friday released the Biosimilar User Fee Act (II) performance goals letter, drawing support from trade groups representing biotechnology companies. 
     

  • Teva launches authorized Cubicin generic
    JERUSALEM — Teva on Thursday announced the U.S. launch of its authorized generic of Cubicin (daptomycin for injection).  The drug is indicated to treat complicated skin and skin structure infections staphylococcus aureus, streptococcus pyogenes, streptococcus dysgalactiae subspecies equisimiis and enterococcus faecalis. 
     
    The drug had about $1.2 billion in U.S. sales as of July 2016, according to IMS Health data. The authorized generic will be sold in vials of 500 mg. 
     

  • Latest CDC report underscores importance in HBP medication adherence

    ATLANTA - Some 5 million Medicare Part D enrollees age 65 and older are not taking their blood pressure medicine properly, increasing their risk of heart disease, stroke, kidney disease and death, according to a new Vital Signs report from the Centers for Disease Control and Prevention released Tuesday.

  • GAO report: Despite some increases, Part D generics prices down since 2010
    WASHINGTON — In spite of some “extraordinary” price increases, a new report from the U.S. Government Accountability Office is showing that overall, generics prices declined under Medicare Part D between 2010 and 2015. 
     
X
This ad will auto-close in 10 seconds